NEW
YORK, May 11, 2023 /PRNewswire/ -- Actinium
Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the
Company), a leader in the development of targeted radiotherapies,
today announced that an abstract has been accepted for oral
presentation at the upcoming European Hematology Association 2023
Congress (EHA), which will be held in Frankfurt, Germany June
8-11, 2023. The abstract includes data from Actinium's
SIERRA controlled phase 3 study comparing the efficacy of Iomab-B
based conditioning, a first-in-class targeted radiotherapy, versus
physician's choice of conventional care in older,
relapsed/refractory acute myeloid leukemia with active disease.
This latest acceptance of the SIERRA trial results at EHA, a major
medical conference, is helping spread awareness about the potential
of Iomab-B in facilitating transplants for patients who are
currently not transplantable.
Details of the EHA presentation are as follows:
Presentation Title: SIERRA trial results with a
targeted radiotherapy, Iomab-B, a myeloablative conditioning with
reduced intensity tolerability yields high CR, long term survival
in HSCT ineligible active r/r AML
Session Type/Title: Oral / SCT Clinical
Date and Time: June 10,
11:30am – 12:45pm CET
About Actinium
Actinium Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company developing targeted radiotherapies to
deliver cancer-killing radiation with cellular level precision to
treat patients with high unmet needs. Actinium's clinical pipeline
is led by targeted radiotherapies that are being applied to
targeted conditioning, which is intended to selectively deplete a
patient's disease or cancer cells and certain immune cells prior to
a bone marrow transplant (BMT), gene therapy or adoptive cell
therapy, such as CAR-T, to enable engraftment of these transplanted
cells with minimal toxicities. Our lead product candidate, Iomab-B
(I-131 apamistamab) has been studied in over four hundred patients,
including the pivotal Phase 3 Study of Iomab-B in Elderly Relapsed
or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT
conditioning. The SIERRA trial was positive with Iomab-B meeting
the primary endpoint of durable Complete Remission of 6-months with
high statistical significance (p<0.0001). Iomab-B enabled 100%
of patients to access a BMT and produced higher rates of post-BMT
CR. Iomab-B produced positive results for the secondary endpoints
of the SIERRA trial including reducing the probability of an event
by 78% resulting in an Event-Free Survival (EFS) Hazard Ratio of
0.22 (p<0.0001), doubled 1-year overall survival and median
overall survival. Iomab-ACT, low dose I-131 apamistamab, is being
studied as a targeted conditioning agent in a Phase 1 study with a
CD19 CAR T-cell Therapy with Memorial Sloan Kettering Cancer Center
with NIH funding. Actimab-A, our second most advanced product
candidate has been studied in approximately 150 patients with Acute
Myeloid Leukemia or AML, including in combination trials with the
chemotherapy regimen CLAG-M and with venetoclax, a targeted
therapy. Actimab-A or lintuzumab-Ac225 is an Actinium-225 based
antibody radiation conjugate targeting CD33, a validated target in
AML. Actinium has entered into a Cooperative Research and
Development Agreement (CRADA) with the National Cancer Institute
(NCI) to develop Actimab-A as a single agent or combination with
chemotherapy, targeted agents or immunotherapy in Phase 1, 2 or 3
trials. The NCI will fund clinical trial expenses under the CRADA
while Actinium will supply Actimab-A. The NCI is currently
accepting proposals for non-clinical and clinical studies with
Actimab-A. Actinium is a pioneer and leader in the field of
Actinium-225 alpha therapies with an industry leading technology
platform comprising over 200 patents and patent applications
including methods of producing the radioisotope AC-225. Our
technology and expertise have enabled collaborative research
partnerships with Astellas Pharma, Inc. for solid tumor
theranostics, with AVEO Oncology Inc. to create an Actinium-225
HER3 targeting radiotherapy for solid tumors, and with EpicentRx,
Inc. to create targeted radiotherapy combinations with their novel,
clinical stage small molecule CD47-SIRPα inhibitor. More
information is available on Actinium's website:
https://www.actiniumpharma.com/.
Forward-Looking Statements
This press release may contain projections or other
"forward-looking statements" within the meaning of the
"safe-harbor" provisions of the private securities litigation
reform act of 1995 regarding future events or the future financial
performance of the Company which the Company undertakes no
obligation to update. These statements are based on management's
current expectations and are subject to risks and uncertainties
that may cause actual results to differ materially from the
anticipated or estimated future results, including the risks and
uncertainties associated with preliminary study results varying
from final results, estimates of potential markets for drugs under
development, clinical trials, actions by the FDA and other
governmental agencies, regulatory clearances, responses to
regulatory matters, the market demand for and acceptance of
Actinium's products and services, performance of clinical research
organizations and other risks detailed from time to time in
Actinium's filings with the Securities and Exchange Commission (the
"SEC"), including without limitation its most recent annual report
on form 10-K, subsequent quarterly reports on Forms 10-Q and Forms
8-K, each as amended and supplemented from time to time.
Contact:
Matthew Beck
Vice President Investor Relations & Communications
mbeck@actiniumpharma.com
(917) 415-1750
View original content to download
multimedia:https://www.prnewswire.com/news-releases/actinium-pharma-announces-iomab-b-sierra-trial-results-accepted-for-oral-presentation-at-the-european-hematology-association-2023-congress-eha-301822394.html
SOURCE Actinium Pharmaceuticals, Inc.